Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
Diabetes, Obesity and Metabolism · 2025-11 · 27 (11) · 6200-6209
DOI: 10.1111/dom.70004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.08.2025. Verfasst von Jason M Samuels und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Obesity, Tirzepatide. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Aims
Trials of the Glucagon‐like Peptide‐1 Receptor Agonists (GLP1RAs) found mean weight losses of 15%–21%, yet realworld dose titration and persistence remain suboptimal, limiting effectiveness. This study aims to determine real‐world titration, persistence and effectiveness of GLP1RAs in patients managed within a multidisciplinary obesity clinic. Materials and Methods This is a singlecentre, retrospective cohort study of patients seen in a multidisciplinary obesity clinic at an academic medical centre from January 2022 to December 2024. Consecutive patients aged 18–75 years enrolled in a ‘no cost to patient’ Medical Weight Loss Bundle program who received ≥1 prescription fill of semaglutide or tirzepatide. Of 2855 enrollees, 2306 (81%) received at least one GLP1RA prescription. The primary outcome was persistence with GLP1RA therapy (continuous prescription fills without a gap ≥84 days). Secondary measures included titration adherence and percentage change in body weight.
Results
Among 2306 patients (median age 46.0 years, Interquartile Ratio [IQR] 38.0–55.0; 85% female; 68% White, 28% Black, 4% Hispanic), with median persistence 10.7 months (IQR 5.4–16.3). Semaglutide was used by 1614 (70%), tirzepatide by 117 (5%), and both agents by 575 (25%). Of semaglutide users, 81% escalated to ≥1 mg and 23% to 2.4 mg; of tirzepatide users, 75% received ≥10 mg and 28% received 15 mg. Among patients persistent for ≥6 months, median weight loss was 9.4% (IQR 6.0%–13.4%); for those persistent for ≥12 months, median weight loss was 14.4% (IQR 9.5%–20.5%).
Conclusions
GLP1RA persistence and dosetitration adherence were moderate but weight loss approximated that seen in clinical trials, supporting real‐world effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
- Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
ORCID-Profile: Jason M Samuels, Heidi Silver
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism, 27(11), 6200-6209. https://doi.org/10.1111/dom.70004
Vancouver
Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism. 2025;27(11):6200-6209. doi:10.1111/dom.70004
BibTeX
@article{Samuels2025,
author = {Samuels, Jason M and Ye, Fei and Irlmeier, Rebecca and Silver, Heidi and Srivastava, Gitanjali and Spann, Matthew},
title = {Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {11},
pages = {6200--6209},
doi = {10.1111/dom.70004}
}
EUVIMED